TCMP
DGX icon

Thrive Capital Management (Pennsylvania)’s Quest Diagnostics DGX Stock Holding History

Thrive Capital Management (Pennsylvania)’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-22,798
Closed -$4.34M – 176
2025
Q3 		$4.34M Buy
22,798
+4,322
+23% +$767K 1.12% 21
2025
Q2 		$3.32M Buy
18,476
+8,639
+88% +$1.5M 1.04% 34
2025
Q1 		$1.66M Sell
9,837
-5,652
-36% -$928K 0.99% 31
2024
Q4 		$2.34M Buy
15,489
+3,234
+26% +$503K 1.07% 42
2024
Q3 		$1.9M Sell
12,255
-1,378
-10% -$206K 0.9% 36
2024
Q2 		$1.87M Buy
13,633
+4,691
+52% +$642K 0.85% 38
2024
Q1 		$1.19M Buy
+8,942
New +$1.16M 0.63% 33

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Thrive Capital Management (Pennsylvania)'s DGX Position: Q4 2025 in Review

Thrive Capital Management (Pennsylvania) sold out of Quest Diagnostics (DGX) in Q4 2025, closing a stake of 22,798 shares — an estimated $4.34M sold.

Thrive Capital Management (Pennsylvania) first reported a position in DGX in Q1 2024 and held it in 7 quarters. The position peaked at $4.34M in Q3 2025. 1,049 funds tracked by Wall St. Rank hold DGX as of Q4 2025.

  • Thrive Capital Management (Pennsylvania) reported no remaining Quest Diagnostics position as of Q4 2025 after selling out during the quarter.
  • Thrive Capital Management (Pennsylvania) sold 22,798 Quest Diagnostics shares in Q4 2025, an estimated $4.34M.
  • Thrive Capital Management (Pennsylvania) first reported a position in Quest Diagnostics in Q1 2024 and held it in 7 quarters.
  • Thrive Capital Management (Pennsylvania)'s Quest Diagnostics position peaked at $4.34M in Q3 2025.
  • 1,049 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2025.

Based on Thrive Capital Management (Pennsylvania)'s 13F filing for Q4 2025, filed 9 Feb 2026.